BioCentury | Jan 16, 2021
Translation in Brief

Dyne’s POC myotonic dystrophy data; plus pulmonary T cell subset contributes to local antibody production after reinfection, DiosCURE’s COVID candidates and more

Dyne’s myotonic dystrophy antisense therapy reduces gene expressionDyne Therapeutics Inc. (NASDAQ:DYN) reported data from a new mouse model of severe disease showing its myotonic dystrophy type 1 (DM1) antisense oligonucleotide therapy reduced nuclear DMPK RNA levels...
BioCentury | Jan 8, 2021
Product Development

Jan. 7 Quick Takes: Sarepta tumbles after hours on DMD miss; plus InnoCare, AstraZeneca, Astellas and Autolus

Sarepta microdystrophin gene therapy misses endpointShares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) fell 50% to $84.45 in after-hours trading after  microdystrophin gene therapy SRP-9001 missed the primary functional endpoint of improvement in NSAA total score compared to...
BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

Myeloid is engineering monocytes as cellular cancer therapies by programming pluripotent myeloid cells to target tumor cells and conduct a suite of myeloid antitumor functions. Ronald Vale and Siddhartha Mukherjee are among the founders of...
BioCentury | Jan 5, 2021
Product Development

IRAK4 inhibitor pipeline: Data Byte

Several inflammatory and cancer indications will soon see human proof-of-concept data from small molecules targeting the kinase IRAK4, as a class of at least eight such molecules makes its way through early-stage trials. IRAK4 mediates innate...
BioCentury | Jan 1, 2021

Another year of firsts in FDA’s new drug approvals

The COVID-19 pandemic didn’t stand in the way of new drug approvals by FDA in 2020, but few new modalities crossed the finish line despite the clinical development fervor around platform technologies and...
BioCentury | Dec 17, 2020

GSK adds to next-generation checkpoint pipeline with Surface deal

GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. ...
BioCentury | Dec 15, 2020
Product Development

Vaccines march forward & CAR Ts move earlier: a BioCentury podcast

On the latest edition of the BioCentury this Week podcast, BioCentury editors discuss the latest advances and setbacks among COVID-19 vaccines in the wake of FDA’s emergency use authorization on Friday for Pfizer and BioNTech’s...
BioCentury | Dec 15, 2020

ADC Therapeutics caps year of milestones by building bridge to China via Hillhouse-backed Overland’s debut deal

Hillhouse-backed Overland’s first deal — the establishment of JV with four cancer programs from Swiss biotech ADC Therapeutics — underscores the start-up’s intent to leverage the “biotech ecosystem...
BioCentury | Dec 11, 2020
Product Development

CAR Ts make the move to earlier lines of treatment despite access barriers

CAR T manufacturers and payers are still negotiating access for B cell lymphoma patients without other treatment options, but that hasn’t stopped companies from pressing on into earlier lines of treatment....
BioCentury | Dec 10, 2020

More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

Weeks after Merck & Co.’s multibillion dollar takeout of VelosBio, Boehringer believes its purchase of NBE in a smaller deal will give it an earlier-stage, best-in-class product against the same target. Boehringer Ingelheim GmbH will acquire...
Items per page:
1 - 10 of 3777